Literature DB >> 8382511

Saturation of tumour cell surface receptors for urokinase-type plasminogen activator by amino-terminal fragment and subsequent effect on reconstituted basement membranes invasion.

H Kobayashi1, H Ohi, H Shinohara, M Sugimura, T Fujii, T Terao, M Schmitt, L Goretzki, N Chucholowski, F Jänicke.   

Abstract

Single-chain urokinase-type plasminogen activator (pro-uPA) is bound to a specific surface receptor on ovarian cancer HOC-I cells that is incompletely saturated. Saturation of uncovered receptors by uPA polypeptides with intact amino-terminal fragment (ATF) derived from pro-uPA by limited proteolysis (human leucocyte elastase [HLE] or V8 protease) has been studied. HOC-I cells preferentially invaded reconstituted basement membranes in a time- and plasminogen-dependent manner. This process was inhibitable by preincubation with uPA polypeptides in the medium at levels which suggested that complete saturation of cell surface uPA receptors occurred. This result indicates that occupation of uPA receptors by enzymatically inactive uPA fragments or prevention of rebinding of pro-uPA synthesised by tumour cells to the receptors specifically reduces the invasion of the tumour cells through basement membranes in vitro.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382511      PMCID: PMC1968269          DOI: 10.1038/bjc.1993.99

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  41 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 2.  Tumor invasion and the extracellular matrix.

Authors:  L A Liotta; C N Rao; S H Barsky
Journal:  Lab Invest       Date:  1983-12       Impact factor: 5.662

3.  Effect of natural protease inhibitors and a chemoattractant on tumor cell invasion in vitro.

Authors:  U P Thorgeirsson; L A Liotta; T Kalebic; I M Margulies; K Thomas; M Rios-Candelore; R G Russo
Journal:  J Natl Cancer Inst       Date:  1982-11       Impact factor: 13.506

4.  The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A chain.

Authors:  W A Günzler; G J Steffens; F Otting; S M Kim; E Frankus; L Flohé
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1982-10

5.  Fibronectin: purification, immunochemical properties, and biological activities.

Authors:  E Ruoslahti; E G Hayman; M Pierschbacher; E Engvall
Journal:  Methods Enzymol       Date:  1982       Impact factor: 1.600

6.  Experimental model for quantitative study of metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

7.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

8.  Membrane invasion culture system (MICS).

Authors:  K R Gehlsen; H N Wagner; M J Hendrix
Journal:  Med Instrum       Date:  1984 Sep-Oct

9.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

Authors:  J D Vassalli; D Baccino; D Belin
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

10.  Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate.

Authors:  R Picone; E L Kajtaniak; L S Nielsen; N Behrendt; M R Mastronicola; M V Cubellis; M P Stoppelli; S Pedersen; K Danø; F Blasi
Journal:  J Cell Biol       Date:  1989-02       Impact factor: 10.539

View more
  4 in total

1.  Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor.

Authors:  Young C Shin; William R Folk
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.

Authors:  D Morrissey; J O'Connell; D Lynch; G C O'Sullivan; F Shanahan; J K Collins
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

3.  Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice.

Authors:  O Wilhelm; M Schmitt; S Höhl; R Senekowitsch; H Graeff
Journal:  Clin Exp Metastasis       Date:  1995-07       Impact factor: 5.150

4.  Anti-metastatic therapy by urinary trypsin inhibitor in combination with an anti-cancer agent.

Authors:  H Kobayashi; H Shinohara; J Gotoh; M Fujie; S Fujishiro; T Terao
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.